Quick Answer
Viridian Therapeutics, Inc.DE reported Total Revenue of $4.00 million for fiscal year 2017.
Viridian Therapeutics, Inc.DE Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2017 | $4.00M | +15.1% |
| 2016 | $3.48M | +37.0% |
| 2015 | $2.54M | -41.2% |
| 2014 | $4.32M | +0.1% |
| 2013 | $4.32M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| March 31, 2018 | $4.78M | +935.5% | +193.3% |
| September 30, 2017 | $1.63M | +74.3% | +127.2% |
| June 30, 2017 | $718.0K | -35.6% | +55.4% |
| March 31, 2017 | $462.0K | -49.6% | -50.6% |
| September 30, 2016 | $936.0K | +86.8% | -16.1% |
| June 30, 2016 | $1.11M | +51.9% | +21.6% |
| March 31, 2016 | $917.0K | +42.2% | +83.0% |
| September 30, 2015 | $501.0K | -61.5% | -31.7% |
- Viridian Therapeutics, Inc.DE showed an increase of +15.1% in Total Revenue compared to the prior fiscal year.
- Over the 2013–2017 period, Viridian Therapeutics, Inc.DE’s total revenue has declined by 7.3% (from $4.32 million to $4.00 million).
- The most recent figure is from Viridian Therapeutics, Inc.DE’s fiscal year 2017 report (Form 10-K), filed with the SEC on March 15, 2018.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: